KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $544.7 million.

  • Halozyme Therapeutics' Operating Expenses rose 34459.34% to $544.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $927.6 million, marking a year-over-year increase of 9998.0%. This contributed to the annual value of $927.6 million for FY2025, which is 9998.0% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Operating Expenses of $544.7 million as of Q4 2025, which was up 34459.34% from $136.3 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Operating Expenses ranged from a high of $544.7 million in Q4 2025 and a low of $38.3 million during Q1 2021
  • Its 5-year average for Operating Expenses is $122.2 million, with a median of $120.4 million in 2022.
  • In the last 5 years, Halozyme Therapeutics' Operating Expenses plummeted by 984.52% in 2024 and then skyrocketed by 34459.34% in 2025.
  • Halozyme Therapeutics' Operating Expenses (Quarter) stood at $45.5 million in 2021, then surged by 135.3% to $107.0 million in 2022, then grew by 20.58% to $129.0 million in 2023, then dropped by 5.04% to $122.5 million in 2024, then skyrocketed by 344.59% to $544.7 million in 2025.
  • Its last three reported values are $544.7 million in Q4 2025, $136.3 million for Q3 2025, and $123.3 million during Q2 2025.